GSK kicks off Phase III programme for daprodustat
GlaxoSmithKline has begun Phase III development of daprodustat, testing its potential as a treatment for anaemia associated with chronic kidney disease (CKD).
Read More
Tag: ASCEND-D
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
